Active Ingredient History
Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (thrombin) and factor Xa. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Thromboembolism (approved 1991)
Acute Coronary Syndrome (Phase 4)
Antithrombin III Deficiency (Phase 4)
Aortic Valve Insufficiency (Phase 4)
Aortic Valve Stenosis (Phase 4)
Blood Coagulation (Phase 3)
Cardiopulmonary Bypass (Phase 3)
Coronary Artery Bypass (Phase 2)
COVID-19 (Phase 2)
Deficiency Diseases (Phase 2)
Disseminated Intravascular Coagulation (Phase 2)
Drugs, Investigational (Phase 1)
Extracorporeal Membrane Oxygenation (Phase 3)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 1)
Hepatic Veno-Occlusive Disease (Phase 2)
Liver Cirrhosis (Phase 1)
Mitral Valve Insufficiency (Phase 4)
Mitral Valve Stenosis (Phase 4)
Neonatology (Phase 4)
Postoperative Hemorrhage (Phase 1)
Pre-Eclampsia (Phase 3)
Reperfusion Injury (Phase 2)
Thoracic Surgery (Phase 2)
Thrombosis (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
